Document is current
Any future updates will be listed below
-
Authors
Zorrilla, Erik
Della Pietra, Adriana
Russo, Andrew F.
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs (VA-ORD I50 RX003002)
National Institutes of Health (NS075599)
- License Information
-
More Information
Article History
Received: 17 May 2024
Accepted: 1 October 2024
First Online: 16 October 2024
Declarations
:
: Not applicable.
: Not applicable.
: AFR and ADP are on the editorial board of The Journal of Headache and Pain. AFR serves as a consultant for Pfizer, Paragon, Eli Lilly, Schedule One Therapeutics, AbbVie, Lundbeck, owns stock in Schedule One Therapeutics, and holds patents for uses of the CGRP monoclonal antibody, PACAP monoclonal antibody, and the CGRP gene enhancer.
